查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018849

尿道结石治疗器械市场：全球市场预测（按器械类型、治疗方法、器械材料、应用和最终用户划分），2026年至2032年

Urolithiasis Management Devices Market by Device Type, Treatment Type, Device Material, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，用于治疗尿道结石的设备的市场规模将达到 5.2703 亿美元，到 2026 年将增长到 5.691 亿美元，到 2032 年将达到 9.037 亿美元，复合年增长率为 8.00%。

主要市场统计数据
基准年 2025 5.2703亿美元
预计年份：2026年 5.691亿美元
预测年份 2032 9.037亿美元
复合年增长率 (%) 8.00%

全面概述当前临床实践、技术创新以及影响尿道结石结石治疗设备研发和推广的相关人员压力。

用于治疗尿道结石的器械正处于工程创新、不断发展的临床方案和不断变化的医疗服务模式的交汇点。过去十年，影像学、内视镜视觉化技术的进步以及体内能量传递的逐步改进，共同拓展了治疗选择，并优化了患者照护流程。本文概述了当前泌尿系统结石治疗领域的现状，重点阐述了器械设计、材料科学和手术人体工学如何不断改进，以优化结石清除和患者康復，同时最大限度地减少创伤。

图表展示了由小型化设备、一次性技术和整合数位平台带来的变革性变化：这些正在重塑行动和实施的流程。

尿道结石的治疗现状正经历着变革，这主要得益于器械小型化、能量输送方式的进步以及数位化诊断技术的融合。小型化的输尿管镜和软式内视镜扩大了内视镜可治疗的结石范围，减少了对侵入性手术的依赖。同时，体内碎石术的进步，特别是雷射平台在碎石效率和热安全性之间的平衡性提升，正在改变治疗方案，并增加可在门诊完成的病例数量。

分析 2025 年关税制度的变化和贸易结构调整将如何影响整个医疗设备供应链的筹资策略、成本结构和采购韧性。

2025年的关税政策变化和国际贸易趋势为製造商、供应商和医疗器材买家带来了新的营运考量。某些医疗设备组件关税的提高，以及地缘政治发展引发的供应链重组，迫使相关人员重新评估筹资策略和成本结构。重要的是，这些贸易措施凸显了建立能够应对跨境成本和前置作业时间波动的弹性采购结构的必要性。

将医疗设备类型、治疗方法、材料、临床应用和最终用户需求与策略性产品定位连结起来的详细细分见解。

有效的市场区隔分析揭示了临床需求、技术适用性和购买行为之间的交集。基于医疗设备类型，市场研究涵盖导管导引线、碎石器、支架和输尿管镜等领域，每种器材都展现出其独特的发展轨迹。导管导引线专注于尖端控制和涂层技术；碎石器追求高效碎石并最大限度减少对周围组织的影响；支架透过材料科学优化患者舒适度和抗粘连性；输尿管镜则在光学性能、柔软性和耐用性之间寻求平衡。依治疗方法，市场分析涵盖体外震波碎石术、体内碎石术和经皮肾镜取石术，每种治疗方法对能量输送、入路器械和影像整合等方面都有其独特的器械需求。

关键区域考虑因素概述了主要区域在法规、报销和临床实践环境方面的差异如何影响医疗设备的引进和商业化。

区域趋势影响临床实务模式、监管路径和报销环境，进而影响医疗设备的设计和市场进入策略。在美洲，微创技术在医疗保健系统中广泛应用，且营运效率和以患者为中心的疗效证据备受重视，因此供应商不仅需要提供临床数据，还需要提供卫生经济学的论述。该地区的采购週期通常受到整合医疗网络和联合采购组织的影响，这进一步凸显了扩充性的供应模式和服务支援的重要性。

深入洞察老牌巨头和敏捷创新者如何透过产品设计、服务模式和策略伙伴关係实现差异化竞争考察。

竞争格局由成熟的医疗设备製造商、创新医疗技术Start-Ups和专业零件供应商组成，各方都采取差异化策略，力求赢得临床机构的青睐和采购部门的关注。领先的产品开发团队致力于将设计能力与临床医生的工作流程相匹配，强调人体工学、直觉的操作以及与影像系统的互通性。随着医院和手术中心寻求能够提供培训、维护和数据分析以优化设备使用的合作伙伴，合约和售后支援能力正日益成为供应商之间重要的差异化因素。

透过协调产品设计、製造灵活性、供应链韧性和证据生成，加速临床部署和商业性成功的实用建议。

产业领导企业应采取多管齐下的方法，使研发重点与实际临床工作流程和采购需求保持一致。首先，优先考虑人性化的设计，以缩短手术时间，提高使用者的人体工学舒适度，并确保新型医疗设备与现有成像和导航系统无缝整合。其次，投资于模组化和扩充性的生产策略，以实现可重复使用和一次性生产路线之间的快速转换，从而解决感染控制问题并满足采购偏好。

采用透明的混合方法调查方法，结合对临床医师的访谈、技术文献回顾和情境分析，来检验趋势和影响。

本研究采用混合方法，将一手质性研究与二手公共资讯来源和技术文献结合。一手资讯来源包括对关键专科临床医生、不同医疗机构的采购经理以及行业高管进行的结构化访谈，旨在检验技术趋势并识别营运挑战。二手资料包括同行评审的临床研究、监管申报文件、医疗设备技术规范以及专业协会发布的公开指南，以确保技术准确性和语境一致性。

摘要重点阐述了临床创新、营运实际情况和策略需求之间的融合，这些融合将决定尿道结石治疗装置未来发展的走向。

尿道结石的治疗正处于一个转折点，医疗设备的迭代创新、手术流程的演变以及供应链的复杂性正在重塑临床路径。内视镜柔软性、能量传输和一次性技术的进步正在拓展微创治疗的选择范围，并加速向门诊治疗的转变。同时，贸易趋势和区域差异要求制定更精细的筹资策略和更贴近本地市场的商业化方案。因此，决策者必须权衡技术进步的潜力与供应链韧性和实证价值等实际因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：尿道结石治疗器械市场：依器械类型划分

  • 导管导引线
  • 破碎机
  • 支架
  • 输尿管镜

第九章：尿道结石（依治疗方法划分）

  • 体外震波碎石术
  • 体内取石术
  • 经皮肾镜取石术

第十章：尿道结石治疗器械市场－依器械材料划分

  • 金属基元件
  • 聚合物元件

第十一章：尿道结石治疗器材市场：依应用领域划分

  • 膀胱结石
  • 肾结石
  • 输尿管结石

第十二章：尿道结石治疗设备市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十三章：尿道结石治疗器材市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：尿道结石治疗器械市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：尿道结石治疗器械市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国尿道结石治疗器械市场

第十七章：中国尿道结石治疗器械市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced MedTech Holdings
  • AKSM, Ltd.
  • Avvio Medical, Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Calyxo Inc.
  • Coloplast A/S
  • Cook Group Incorporated
  • DirexGroup
  • Dornier MedTech GmbH
  • Dyne Medical Group Inc.
  • EMS Electro Medical Systems SA
  • EDAP TMS SA
  • Elmed Lithotripsy Systems
  • EndoTheia, Inc.
  • Karl Storz GmbH & Co. KG
  • Nissha Medical Technologies
  • Olympus Corporation
  • Quanta System SpA
  • Richard Wolf GmbH
  • Siemens Healthineers
  • SonoMotion
  • Teleflex Incorporated
Product Code: MRR-ED54C46E9009

The Urolithiasis Management Devices Market was valued at USD 527.03 million in 2025 and is projected to grow to USD 569.10 million in 2026, with a CAGR of 8.00%, reaching USD 903.70 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 527.03 million
Estimated Year [2026] USD 569.10 million
Forecast Year [2032] USD 903.70 million
CAGR (%) 8.00%

A comprehensive introduction that frames current clinical practices, technological innovation, and stakeholder pressures shaping urolithiasis device development and adoption

Urolithiasis management devices occupy a dynamic intersection of engineering innovation, evolving clinical protocols, and shifting care delivery models. Over the past decade, incremental improvements in imaging, endoscopic visualization, and intracorporeal energy delivery have converged to expand treatment options and refine patient pathways. This introduction synthesizes the current landscape by highlighting how device design, material science, and procedural ergonomics are increasingly tailored to minimize invasiveness while optimizing stone clearance and patient recovery.

Clinicians now prioritize devices that offer reproducible outcomes with predictable safety profiles, and manufacturers respond by focusing on modularity, single-use options, and integration with digital platforms for procedural guidance. Payers and health systems demand demonstrable improvements in throughput and post-procedure resource utilization, which in turn shapes procurement preferences. In sum, the sector is characterized by rapid technical iteration, growing emphasis on user experience, and a continuous recalibration of value propositions to meet clinical and economic performance requirements.

Illustration of transformative shifts driven by device miniaturization, disposable technologies, and integrated digital platforms reshaping procedural pathways and adoption

The landscape of urolithiasis management is undergoing transformative shifts driven by advances in device miniaturization, energy delivery modalities, and integration of digital diagnostics. Miniaturized ureteroscopes and flexible endoscopes are widening the spectrum of stones that can be managed endoscopically, reducing reliance on more invasive procedures. Concurrently, enhancements in intracorporeal lithotripsy-particularly the refinement of laser platforms that balance fragmentation efficiency with thermal safety-have altered procedural algorithms, increasing case volumes that can be completed in ambulatory settings.

Beyond pure device performance, there is a pronounced movement toward disposability and single-use technologies to address infection control concerns and streamline sterilization workflows. The rise of data-enabled devices that provide procedural analytics and imaging enhancement tools is creating opportunities for outcome tracking and operator training. Moreover, regulatory expectations and reimbursement frameworks are evolving in tandem, encouraging manufacturers to demonstrate not only clinical efficacy but also measurable operational benefits, which reshapes product positioning and commercialization strategies.

Analysis of how evolving tariff regimes and trade realignments in 2025 are influencing sourcing strategies, cost structures, and procurement resilience across the device supply chain

Tariff policy changes and international trade dynamics in 2025 have introduced new operational considerations for manufacturers, suppliers, and healthcare purchasers. Increased duties on specific medical device components, coupled with supply chain realignments catalyzed by geopolitical developments, have compelled stakeholders to reassess sourcing strategies and cost structures. Importantly, these trade measures have emphasized the need for resilient procurement frameworks that account for variable cross-border costs and lead times.

In response, many organizations are diversifying supplier bases and evaluating nearshoring opportunities to mitigate exposure to import-related volatility. Device designers are also reconsidering bill-of-materials choices, favoring materials and subcomponents that are locally available or subject to lower trade barriers. For clinical providers, procurement teams are increasingly incorporating total-cost-of-ownership analyses that account for tariff impacts, logistics, and inventory buffers, thereby influencing purchasing cycles and contractual arrangements with manufacturers and distributors.

Deep segmentation insights that connect device types, treatment modalities, materials, clinical applications, and end-user requirements to strategic product positioning

Effective segmentation analysis illuminates where clinical need, technology fit, and purchasing behavior intersect. Based on Device Type, the landscape is studied across Guidewires, Lithotripters, Stents, and Ureteroscopes, revealing distinct development trajectories: guidewires emphasize tip control and coating technology, lithotripters pursue energy-efficient fragmentation with minimal collateral tissue effect, stents optimize patient comfort and encrustation resistance through material science, and ureteroscopes balance optics with flexibility and durability. Based on Treatment Type, the market is studied across Extracorporeal Shock Wave Lithotripsy, Intracorporeal Lithotripsy, and Percutaneous Nephrolithotomy, and each modality drives unique device requirements related to energy delivery, access instrumentation, and imaging integration.

Based on Device Material, the market is studied across Metal-Based Devices and Polymer-Based Devices, which underlines trade-offs between strength, flexibility, cost, and biocompatibility that influence clinical selection and lifecycle management. Based on Application, the market is studied across Bladder Stones, Kidney Stones, and Ureteral Stones, highlighting how stone location dictates access strategy, instrument size, and post-procedural follow-up. Finally, based on End User, the market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, with each setting prioritizing different value drivers such as throughput, device turnaround time, or procedural complexity. Taken together, these segmentation lenses provide a multi-dimensional view that informs product development priorities and commercialization tactics.

Key regional considerations outlining how divergent regulatory, reimbursement, and clinical practice environments across major geographies shape device adoption and commercialization

Regional dynamics influence clinical practice patterns, regulatory pathways, and reimbursement landscapes, which in turn shape device design and go-to-market strategies. In the Americas, health systems exhibit a high adoption rate of minimally invasive techniques and place strong emphasis on evidence demonstrating operational efficiency and patient-centered outcomes, prompting vendors to support health economic narratives alongside clinical data. Procurement cycles in this region are often influenced by integrated delivery networks and group purchasing organizations, which amplifies the importance of scalable supply models and service support.

In Europe, Middle East & Africa, heterogeneity in regulatory expectations and payer structures requires adaptable market entry strategies that balance localized clinical validation with flexible commercial models. Stakeholders in this region may prioritize cost-effectiveness and durability, especially in systems with constrained capital allocation. Within the Asia-Pacific region, rapid infrastructure development and high procedure volumes create significant demand for cost-effective, scalable devices and single-use solutions that address infection control and throughput. Across all regions, partnerships with local distributors and targeted clinician engagement remain central to adoption and long-term market development.

Critical competitive insights into how established players and agile innovators are differentiating through product design, service models, and strategic partnerships

The competitive landscape comprises established device manufacturers, innovative medtech startups, and specialized component suppliers, each pursuing differentiated strategies to capture clinical preference and procurement attention. Leading product development teams focus on aligning design features with clinician workflows, emphasizing ergonomics, intuitive controls, and interoperability with imaging systems. Contracting and post-market support capabilities increasingly differentiate suppliers, as hospitals and surgical centers seek partners that provide training, maintenance, and data analytics to optimize utilization.

Concurrently, some companies are adopting focused plays-such as single-use platforms or high-powered laser systems-while others concentrate on incremental improvements to guidewires and stents through advanced materials. Strategic alliances, licensing arrangements, and targeted acquisitions are common tactics used to accelerate capability expansion, particularly in areas like imaging integration and disposable instrument portfolios. Ultimately, companies that combine clinical credibility, supply resilience, and compelling value demonstrations are positioned to lead in a landscape that prizes both innovation and operational performance.

Actionable recommendations that align product design, manufacturing agility, supply chain resilience, and evidence generation to accelerate clinical adoption and commercial success

Industry leaders should adopt a multi-pronged approach that aligns R&D priorities with real-world clinical workflows and procurement demands. First, prioritize human-centered design to reduce procedure time and improve user ergonomics, ensuring that new devices integrate seamlessly with existing imaging and navigation systems. Second, invest in modular and scalable manufacturing strategies that allow rapid shifts between reusable and single-use production pathways, thereby responding to infection control concerns and procurement preferences.

Third, strengthen supply chain resilience by diversifying suppliers, evaluating nearshoring opportunities, and embedding tariff and logistics scenarios into commercial planning. Fourth, cultivate robust clinical evidence and health economic dossiers that speak directly to institutional decision-makers, demonstrating not only clinical outcomes but also downstream operational benefits. Lastly, pursue targeted partnerships with regional distributors and training centers to accelerate adoption, while offering post-sale analytics and education services that support sustained utilization and long-term customer relationships.

A transparent mixed-methods research methodology integrating clinician interviews, technical literature review, and scenario analysis to validate trends and implications

This research synthesis is built on a mixed-methods approach that triangulates primary qualitative engagement with secondary public domain sources and technical literature. Primary inputs included structured interviews with clinicians across key specialties, procurement leads from diverse care settings, and industry executives to validate technology trends and identify operational pain points. Secondary research encompassed peer-reviewed clinical studies, regulatory filings, device technical specifications, and publicly available guidance from professional societies to ensure technical accuracy and context.

Analytical methods combined thematic coding of qualitative interviews with cross-sectional comparison of device features and clinical application requirements. Where applicable, supply chain and policy impacts were assessed through scenario analysis to understand sensitivity to trade and logistics variables. Throughout, findings were corroborated across multiple sources to strengthen validity and presented with transparency about data provenance and methodological limits so that decision-makers can interpret insights with appropriate confidence.

Concluding synthesis highlighting the convergence of clinical innovation, operational realities, and strategic imperatives that will define future progress in urolithiasis device management

The management of urolithiasis is at an inflection point where iterative device innovation, procedural evolution, and supply chain complexities converge to redefine clinical pathways. Advances in scope flexibility, energy delivery, and single-use technologies are expanding minimally invasive options and supporting shifts toward ambulatory care. Meanwhile, trade dynamics and regional heterogeneity necessitate more sophisticated procurement strategies and localized commercialization approaches. Decision-makers must therefore balance the promise of technological improvements with pragmatic considerations around supply resilience and evidence-backed value.

Moving forward, stakeholders who successfully align product development with clinician workflows, invest in demonstrable outcome metrics, and build flexible manufacturing and distribution models will capture the greatest opportunity to influence care delivery. The convergence of clinical needs, regulatory expectations, and operational priorities creates fertile ground for innovations that are not only clinically superior but also operationally compelling, ultimately improving patient outcomes and health system efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urolithiasis Management Devices Market, by Device Type

  • 8.1. Guidewires
  • 8.2. Lithotripters
  • 8.3. Stents
  • 8.4. Ureteroscopes

9. Urolithiasis Management Devices Market, by Treatment Type

  • 9.1. Extracorporeal Shock Wave Lithotripsy
  • 9.2. Intracorporeal Lithotripsy
  • 9.3. Percutaneous Nephrolithotomy

10. Urolithiasis Management Devices Market, by Device Material

  • 10.1. Metal-Based Devices
  • 10.2. Polymer-Based Devices

11. Urolithiasis Management Devices Market, by Application

  • 11.1. Bladder Stones
  • 11.2. Kidney Stones
  • 11.3. Ureteral Stones

12. Urolithiasis Management Devices Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Urolithiasis Management Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Urolithiasis Management Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Urolithiasis Management Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Urolithiasis Management Devices Market

17. China Urolithiasis Management Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced MedTech Holdings
  • 18.6. AKSM, Ltd.
  • 18.7. Avvio Medical, Inc.
  • 18.8. Becton, Dickinson and Company
  • 18.9. Boston Scientific Corporation
  • 18.10. Calyxo Inc.
  • 18.11. Coloplast A/S
  • 18.12. Cook Group Incorporated
  • 18.13. DirexGroup
  • 18.14. Dornier MedTech GmbH
  • 18.15. Dyne Medical Group Inc.
  • 18.16. E.M.S. Electro Medical Systems S.A.
  • 18.17. EDAP TMS SA
  • 18.18. Elmed Lithotripsy Systems
  • 18.19. EndoTheia, Inc.
  • 18.20. Karl Storz GmbH & Co. KG
  • 18.21. Nissha Medical Technologies
  • 18.22. Olympus Corporation
  • 18.23. Quanta System S.p.A.
  • 18.24. Richard Wolf GmbH
  • 18.25. Siemens Healthineers
  • 18.26. SonoMotion
  • 18.27. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY LITHOTRIPTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY LITHOTRIPTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY LITHOTRIPTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETEROSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETEROSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETEROSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY INTRACORPOREAL LITHOTRIPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY INTRACORPOREAL LITHOTRIPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY INTRACORPOREAL LITHOTRIPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY PERCUTANEOUS NEPHROLITHOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY PERCUTANEOUS NEPHROLITHOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY PERCUTANEOUS NEPHROLITHOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY METAL-BASED DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY METAL-BASED DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY METAL-BASED DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY POLYMER-BASED DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY POLYMER-BASED DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY POLYMER-BASED DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY BLADDER STONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY BLADDER STONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY BLADDER STONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY KIDNEY STONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY KIDNEY STONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY KIDNEY STONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETERAL STONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETERAL STONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY URETERAL STONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. GCC UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 130. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. G7 UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 136. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. NATO UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY DEVICE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA UROLITHIASIS MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)